ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingHans‐Joachim Schmoll, Andrés Cervantes, Eric Van Cutsem et al.|Annals of Oncology|2012Cited by 1.5k
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal CancerMarc Peeters, Jennifer Gansert, Timothy Price et al.|Journal of Clinical Oncology|2010Cited by 1k
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal CancerAlberto Sobrero, Howard A. Burris|Journal of Clinical Oncology|2008Cited by 951
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, Geoff Chong et al.|The Lancet|2023Cited by 319
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancerMarc Peeters, R. Sidhu, Timothy Price et al.|Annals of Oncology|2013Cited by 220